Regeneron Pharmaceuticals has extended its agreement with the U.S. government's BARDA to supply additional doses of Inmazeb, an FDA-approved antibody treatment for Ebola caused by Orthoebolavirus zairense. The expanded deal, valued at approximately $270 million, will provide doses through 2031 to support U.S. preparedness against Ebola outbreaks. Inmazeb has been shown to reduce mortality by about 55% in clinical trials and has been administered to hundreds of patients since 2019. Separately, Regeneron is advancing maftivimab, a component of Inmazeb, as a potential treatment for the current Bundibugyo virus outbreak, with ongoing clinical trials and partnerships to enhance outbreak response.
Regeneron Pharmaceuticals Inc (REGN) trades at USD 811.69 on Pluang as of Oct 26, 2026 18:11 WIB, showing a modest 0.83% increase in one day. The company's market cap stands at $82.88 billion, reflecting its significant presence in the health sector. This comes as Regeneron extends its agreement with BARDA to supply additional Ebola treatment doses, reinforcing its role in infectious disease preparedness.
